Forge, which launched in July 2020, has been expanding their Columbus, OH, facilities so that the adeno-associated virus gene therapy products the company develops for its clients can go from discovery to development to the commercial cycle in one space.

"We have the means to continue expanding that facility in a significant way," Maslowski said.

Forge also plans to expand its reach into the European market and will have client development offices in Europe to serve clients there, Maslowski added.

In addition to growing the company's reach and capabilities, Forge looks to have more products in development, Tyrpien said.

"We have two therapeutic products in the pipeline, but we are also looking for new technologies to add into this growing development," Tyrpien said.

Watch the video below to learn more.

Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...

Advances in gene therapy call for education, patient advocate says
Durhane Wong-Rieger, board chair of Rare Diseases International, spoke to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in...

Investment continues in cell and gene sector, despite disruptions
Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's...

Regional government steps in to boost gene therapy manufacturing in Spain
BARCELONA, SPAIN -- Early cooperation between the government of the Basque region in northern Spain and companies can help boost manufacturing of gene...

Meeting on the Med opens with new data and eyes on the money
BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy...